Yazar "Polat, M." seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    Effect of 1,25 (OH)2 D3 Treatment on Lipid Levels in Uremic Hemodialysis Patients
    (1992) Yeksan, M.; Türk, S.; Polat, M.; Çığlı, A.; Erdoğan, Y.
    The aim of this study was to evaluate the effect of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis (HD) patients. Thirty-one HD patients who had never been treated with vitamin D nor related drugs and 12 healthy subjects with normal renal functions were studied. Uremic HD patients were randomly divided into two groups. Sixteen uremic HD patients were treated with oral calcitriol (0.5 ?g/day) for 8 weeks. 13 uremic HD patients and 12 healthy subjects were given placebo. In all these cases before and after 8 weeks of treatments; serum total lipid, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerid levels were determined. After calcitriol treatment, triglycerid levels were significantly decreased. But total lipid, cholesterol, HDL-cholesterol and LDL-cholesterol levels did not significantly change. In the other two groups there were no significant changes. These results show that calcitriol treatment has a positive effect on triglycerid levels in uremic HD patients. This effect of mechanism of calcitriol treatment has not been known yet. But it could be due to regulation carbohydrates metabolism and normalization of parathormone (PTH) levels.
  • Küçük Resim
    Öğe
    Effect of Vitamin E Therapy on Sexual Functions of Uremic Patients in Hemodialysis
    (1992) Yeksan, M.; Polat, M.; Türk, S.; Kazancı, H.; Akhan, G.; Erdoğan, Y.; Erkul, I.
    Twenty-four uremic patients on hemodialysis who had never been treated with vitamin E or related drugs and 12 control patients with normal renal function were studied. Hemodialysis patients were randomly divided into two groups; 12 were treated with oral vitamin E (300 mg/day) for eight weeks and 12 uremic patients and 12 controls were given placebo. Serum vitamin E, prolactin, FSH, LH, and free testosterone levels were measured in all patients before and after treatment. After the vitamin E treatment serum prolactin levels were significantly decreased (50.8 vs 15.4 ng/ml, p<0.01). Vitamin E levels were significantly increased (1.11 vs 1.22 mg/dl, p<0.05). Serum FSH, LH and free testosterone were not affected. In the other two groups there were no significant changes. These results show that vitamin E treatment lowers prolactin levels in uremic hemodialysis patients. This might be due to inhibition of central prolactin secretion. Vitamin E inhibits pituitary gland hypertrophy in vitamin E-deficient rats. (Int J Artif Organs 1992; 15: 648-52)
  • Küçük Resim Yok
    Öğe
    Effect of Vitamin-E Therapy on Sexual Functions of Uremic Patients in Hemodialysis
    (WICHTIG EDITORE, 1992) Yeksan, M.; Polat, M.; Türk, S.; Kazancı, H.; Akhan, G.; Erdoğan, Y.; Erkul, I.
    Twenty-four uremic patients on hemodialysis who had never been treated with vitamin E or related drugs and 12 control patients with normal renal function were studied. Hemodialysis patients were randomly divided into two groups; 12 were treated with oral vitamin E (300 mg/day) for eight weeks and 12 uremic patients and 12 controls were given placebo. Serum vitamin E, prolactin, FSH, LH, and free testosterone levels were measured in ail patients before and after treatment. After the vitamin E treatment serum prolactin levels were significantly decreased (50.8 vs 15.4 ng/ml, p<0.01). Vitamin E levels were significantly increased (1.11 vs 1.22 mg/dl, p<0.05). Serum FSH, LH and free testosterone were not affected. In the other two groups there were no significant changes. These results show that vitamin E treatment lowers prolactin levels in uremic hemodialysis patients. This might be due to inhibition of central prolactin secretion. Vitamin E inhibits pituitary gland hypertrophy in vitamin E-deficient rats.
  • Küçük Resim
    Öğe
    Effects of 1,25 (OH)2 0 3 Treatment on Lipid Levels in Uremic Hemodialysis Patients
    (SAGE PUBLICATIONS LTD, 1992) Yeksan, M.; Türk, S.; Polat, M.; Çığlı, A.; Erdoğan, Y.
    The aim of this study was to evaluate the effect of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis (HD) patients. Thirty-one HD patients who had never been treated with vitamin D nor related drugs and 12 healthy subjects with normal renal functions were studied. Uremic HD patients were randomly divided into two groups. Sixteen uremic HD patients were treated with oral calcitriol (0.5 mug/day) for 8 weeks. 13 uremic HD patients and 12 healthy subjects were given placebo. In all these cases before and after 8 weeks of treatments; serum total lipid, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerid levels were determined. After calcitriol treatment, triglycerid levels were significantly decreased. But total lipid, cholesterol, HDL-cholesterol and LDL-cholesterol levels did not significantly change. In the other two groups there were no significant changes. These results show that calcitriol treatment has a positive effect on triglycerid levels in uremic HD patients. This effect of mechanism of calcitriol treatment has not been known yet. But it could be due to regulation carbohydrates metabolism and normalization of parathormone (PTH) levels.